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Abstract
Background: Many patients with chronic kidney disease (CKD) suffer from fatigue caused by anemia, but that anemia can
be reversed. Successful treatment can be measured as a decrease in fatigue and an increase in energy or vitality, particularly
on the vitality (VT) subscale of the SF-36. Changes in VT scores are most commonly interpreted in terms of minimally
important differences or standardized effect sizes, but neither a minimally important difference nor a standardized effect
size provides information about how patients’ activities are affected. Therefore, we analyzed the association between
differences in VT scores and a variable that is meaningful to patients and to society the frequency of going out.
Study Design: Questionnaire survey. Analyses of differences among participants at bseline, and analyses of differences
within participants over time.
Setting and Participants: CKD patients who were not on dialysis and were involved in a study of anti-anemia therapy.
Predictor: VT scores.
Outcome: Frequency of going out.
Measurements: VT scores and the frequency of going out.
Results: At baseline, higher VT scores and younger age were associated with going out more often, while sex and the
presence of diabetic nephropathy were not associated with the frequency of going out. Greater changes in VT scores over
time were associated with greater changes in the frequency of going out, in univariate and multivariate analyses.
Conclusions: At baseline, VT was associated with the frequency of going out. Increases in VT were also associated with
increases in the frequency of going out. These results show how VT scores can be linked to daily activities that are important
to individual patients and to society.
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Introduction
Anemia causes fatigue in predialysis patients with chronic
kidney disease (CKD). That fatigue is alleviated when Hb levels
increase after treatment with erythropoiesis-stimulating agents
(ESAs). The effects of such treatment are often measured as self-
reported decreases in fatigue and increases in energy or vitality. In
a recent review of 14 studies, Gandra et al. [1] concluded that
ESAs can increase self-reported levels of energy, and a review by
Leaf and Goldfarb came to a similar conclusion [2].
In this context, one question is how scores on the vitality (VT)
subscale of the SF-36 should be interpreted. Changes in VT scores
are most commonly interpreted in terms of minimally important
differences [3] or standardized effect sizes [4]. Minimally
important differences are cutoff points; they can be used to
distinguish treatments that have a pre-specified magnitude of effect
from those that do not. Standardized effect sizes such as Cohen’s d
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express the magnitude of an effect in standard-deviation units and
are often interpreted as ‘‘small,’’ ‘‘large,’’ etc. By itself, however,
neither a minimally important difference nor a standardized effect
size provides information about how differences in vitality affect
CKD patients’ lives.
For example, in a recently reported randomized controlled trial,
patients with chronic kidney disease were given an ESA, with one
of two possible Hb targets [5]. The between-group difference in
the change from the baseline value was 4.8 points on the VT scale,
which is very close to the minimally important difference of 5
points that was suggested by Bjorner et al. [6]. That difference was
also statistically significant (p = 0.025). However, when we ask
what that difference means, then the p value of course gives no
answer, and the minimally important difference is interpretable
only in terms of the population-level phenomena by which it was
originally defined.
Interpretability is recognized as an important characteristic of
patient-reported outcomes [7], and the impact of anemia
treatment on the quality of life of pre-dialysis CKD patients has
been studied [8–10], but connections between VT scores and daily
life are still obscure. Therefore, we analyzed the association
between differences in VT scores and a variable that is not
generally considered to be a direct manifestation of health-related
quality of life, but is nonetheless meaningful to patients and to
society: the frequency of going out (we translate the Japanese gai-
shutsu as ‘‘going out’’). This paper shows how differences in VT
scores, both differences between participants at baseline and
differences over time within participants, could be used to predict
differences in the frequency of going out.
Methods
Data from those patients in Akizawa et al.’s study [5] whose
quality-of-life (QOL) questionnaires at baseline and also at 12
weeks after the start of drug administration were complete,
without regard to the group to which they were assigned, were
analyzed. VT was measured with 4 question items and scored on a
scale from 0 to 100, with higher scores reflecting greater vitality
[11]. The questionnaires also included one question asking about
the frequency of going out. That question had four choices as
responses: ‘‘I almost never go out’’, ‘‘I go out one or two days each
week’’, ‘‘I go out three or four days each week’’, and ‘‘I go out five
or more days each week’’.
The relationship at baseline between VT score and the
frequency of going out was analyzed, as was the relationship
between changes in VT scores and changes in the frequency of
going out.
This study was approved by the Institutional Review Boards at
Ikegami General Hospital, the Medical Corporation of Showakai,
and Kochi Takasu Hospital. All participants giave written
informed consent.
Statistical Analysis
Analyses of data collected at baseline. To analyze the
relationship at baseline between VT score and the frequency of
going out, two logistic-regression models were used. In both
models, the dependent variable was the baseline frequency of
going out, which had been dichotomized into low frequency (fewer
than three times each week) and high frequency (three or more
times each week).
In the simple model (model A), there was only one independent
variable: the baseline VT score. In the more complex model
(model B), sex, age, and the presence or absence of diabetic
nephropathy were included as covariates.
Analyses of changes over time. To model the association
between changes in VT scores and changes in the frequency of
going out, logistic regression was again used.
There were two independent variables: one was the change in
VT score, and the other was that change expressed as a
standardized effect size and then categorized (SES) [4]. The SES
of the change in VT score was computed as follows: (individual
score at 12 weeks – individual score at baseline)/standard
deviation of the scores at baseline.
SES results are often interpreted in terms of categories, and for
this study five categories of SES were defined. The values most
commonly used as ‘‘borders’’ between SES categories are 0.2, 0.5,
and 0.8 [4]. Using those three criteria, we defined the highest
category as ‘‘greater than or equal to 0.8’’, the next lower category
as ‘‘from 0.5 to 0.8’’, and the next lower category as ‘‘from 0.2 to
0.5’’. SES values less than 0.2 include both very small positive
effects and also all negative effects. Therefore, to separate the
positive effects from the negative effects, we defined the two lowest
categories as ‘‘from 0 to 0.2’’ and ‘‘less than 0’’. This gave a total of
five categories.
The dependent variable was the change in the frequency of
going out, after it had been dichotomized into ‘‘increase’’ and ‘‘no
increase’’.
Two simple models, each of which had only one independent
variable (either the change in VT score (model C1) or the category
of SES (model C2)), were tested. More complex models were also
used, in which sex, age, and the presence or absence of diabetic
Table 1. Demographic and clinical characteristics, and the
frequency of going out.








Chronic glomerulonephritis 135 (43.7)






Serum creatinine (mg/dL) 3.5561.07
Ccr (mL/min) 18.7966.67
VT 64.1621.2
Frequency of going out
Almost never 31 (10.0)
1–2 days a week 100 (32.4)
3–4 days a week 78 (25.2)
5 or more days a week 100 (32.4)
Total 309 (100)
doi:10.1371/journal.pone.0040455.t001
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nephropathy were included as covariates (models D1 and D2).
Finally, the more complex models were used again, but after
exclusion of data from the participants who at baseline were in the
lowest category of going out (models E1 and E2). They were
excluded because of concern that increases from the lowest
category might have been caused by regression toward the mean.
For all analyses, alpha= 0.05 (two-sided), and 95% confidence
intervals are shown.
Results
Usable data were obtained from 144 men and 165 women
(Table 1).
Data Collected at Baseline
At baseline (Table 2), higher VT scores were associated with
going out more often. Age was also associated with going out, but
sex and diabetic nephropathy were not.
Changes Over Time
Greater changes in VT scores were associated with greater
changes in the frequency of going out (Table 3), with both the
univariate model (model C1) and the multivariate models (models
D1 and E1). In the multivariate models, none of the covariates had
a p value less than 0.05.
Figure 1 shows, for each SES category, the proportion of
respondents in that category whose frequency of going out
Table 2. Analyses of data collected at baseline: associations of VT score and frequency of going out.
b Standard Error Wald x2 Odds ratio 95% CI P
Model A
Intercept 20.87 0.38 – – – –
VT score as continuous variable 0.019 0.01 10.63 1.02 1.01–1.03 0.001
Model B
Intercept 0.76 0.78 – – – –
VT score as continuous variable 0.02 0.01 10.44 1.02 1.01–1.03 0.001
Age 20.03 0.01 7.91 0.97 0.95–0.99 0.005
Sex (Male) 0.24 0.26 0.91 1.28 0.77–2.12 0.340
Diabetic nephropathy yes/no (non-diabetic
nephropathy)
0.31 0.30 1.05 1.36 0.76–2.44 0.305
doi:10.1371/journal.pone.0040455.t002
Table 3. Associations between the change in VT scores and the improvement in the frequency of going out (VT change score as
the independent variable).
b Standard Error Wald x2 Odds ratio 95%CI P
Model C1
Intercept 21.23 0.14 – – – –
VT change score
(Continuous)
0.03 0.01 13.80 1.03 1.01–1.05 ,0.001
Model D1 (covariates: age, sex, diabetic nephropathy)
Intercept 22.28 0.83 – – – –
VT change score
(Continuous)
0.02 0.01 14.26 1.03 1.01–1.05 ,0.001
Age 0.02 0.01 1.95 1.02 0.99–1.04 0.162




20.06 0.34 0.03 0.94 0.48–1.84 0.855
Model E1: Same as Model D1 except patients at the floor at baseline were excluded to avoid regression to the mean
Intercept 22.17 0.91 – – –
VT change score
(Continuous)
0.02 0.01 7.65 1.02 1.01–1.04 0.005
Age 0.02 0.01 1.25 1.02 0.99–1.04 0.263




20.11 0.39 0.08 0.90 0.42–1.92 0.783
doi:10.1371/journal.pone.0040455.t003
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increased. The frequency of going out increased in approximately
15% of those whose SES was less than 0.2, and it increased in
more than 30% of those whose SES was greater than or equal to
0.2. In these data, an SES of 0.2 was equal to a change in VT
score of 4.2 points.
Figures 2, 3, and 4 show odds ratios and adjusted odds ratios for
increases in the frequency of going out. The SES category of ‘‘less
than zero’’ was the reference category. For both the univariate and
the multivariate models, the patterns are similar to that shown in
Figure 1. None of the covariates in models C2, D2, or E2 had a p
value less than 0.05.
Discussion
The results of the analyses of the baseline data show that VT
was associated with the frequency of going out, and the results of
the analyses of changes over time show that increases in VT were
associated with increases in the frequency of going out.
We expect that documenting such associations will be partic-
ularly important for patient-centered clinical practice, in which it
is necessary to ‘‘translate’’ risk reductions, numbers needed to
treat, and QOL scores into more concrete terms to help patients
understand their meaning and also to give healthcare workers
insights into patients’ lives outside the context of the clinical
encounter.
Reports of QOL scores have become common in many clinical
fields, including clinical nephrology [8], but such reports do not
often give clear ideas about how the scores can be interpreted. For
example, patients may be told that treatment of their anemia can
be expected to increase their VT score by about 5 points (as found
by Akizawa [5]), but of course that alone is not very informative. It
raises the question ‘‘What does a 5-point increase mean?’’ Some
previous studies have approached such questions via the concept
of the minimally important difference. For example, Bjorner et al.
[6] quantified the effects of various medical conditions on VT
scores, as well as the association between VT scores and life events
such as job loss, hospitalization, and death. On the basis of their
results, they proposed that 5 points be used as the minimally
important difference for groups with below-average VT scores.
Applying that criterion, we might expect treatment of anemia to
result in a group-level difference in VT scores that would be
important.
Another common approach to QOL scores involves expressing
differences in standard-deviation units. As noted by Norman et al.
[12], minimally detectable differences are often about 0.5 SDs. In
this study, a VT score difference of about 5 was within the 0.2 to
0.4 range of standardized effect size that is usually called
‘‘medium’’ or ‘‘moderate’’ [2].
Nonetheless, whether we focus on minimally important
differences (quantified by disease and by life events) or on
thresholds in standard-deviation units, the implications from a
patient’s perspective can still be vague. Thus, attention should also
be paid to the link between VT scores and effect indicators that are
more immediately understandable to patients and more directly
relevant to social policies. We examined the frequency of gai-shutsu
as one such effect indicator.
Interpretation of the present results therefore depends greatly on
the meaning of the term gai-shutsu. While we translate it into
English as ‘‘going out’’, it should be kept in mind that gai-shutsu is
generally not used to describe any and all instances of leaving one’s
home. Instead, it is generally used to describe instances of leaving
Figure 1. Relationship between the SES categories of changes
in VT scores and the proportion of participants who had
improvement in the frequency of going out. Comparing the
group with the greatest increase in VT score to the group with a
decrease and to the group with almost no increase, the Figure shows
that more than twice as many people in the former group reported
improvement in their frequency of going out. That is, groups with
greater increases in VT scores had more peole who reported increases
in the frequency of going out.
doi:10.1371/journal.pone.0040455.g001
Figure 2. Association between changes in VT scores and
changes in the frequency of going out. The independent variable
is the categories of SES (SES of ‘‘,0’’ as the reference standard). This
Figure shows the results from model C2, in which the change in VT
score was the only independent variable. Greater changes in VT scores
were clearly associated with going out more frequently.
doi:10.1371/journal.pone.0040455.g002
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either one’s home or one’s workplace for a non-obligatory activity.
Thus, it generally does not include going to work or to school. It
might also not include going to a clinic or a hospital for a pre-
scheduled outpatient appointment. In such a situation one would
probably not use the general term gai-shutsu, but would instead
mention the destination explicitly. Gai-shutsu can include going out
alone, but it also covers many activities done in groups.
With that meaning in mind, these results provide a basis for
seeing changes in VT scores as indicators of patients’ daily lives. In
particular, among older people in Japan and in Japanese society
generally, social isolation and the loosening of family and
community ties are becoming important problems. The propor-
tion of elderly people living alone increased from 4.3% for men
and 11.2% for women in 1980 to 9.7% for men and 19.0% for
women in 2005 [13].
Any resulting tendency toward social isolation might be
alleviated by interventions promoting activities outside the home.
It is reasonable to expect that unemployed elderly people who go
out (in the sense of gai-shutsu, as described above) are less likely to
burden their family or social-service agencies. Increases in vitality
might provide a foundation for increasing gai-shutsu, which would
be both individually and socially beneficial. Another implication of
the present work is that such improvements might be expected
from medical interventions, and specifically from the treatment of
anemia [2].
One important caveat derives from the fact that this study was a
type of secondary analysis. The data were originally collected as
part of a randomized trial of two different targets for anti-anemia
therapy, and the opportunity to use them for the present purpose
was incidental. Therefore these results must not be taken as
definitive and conclusive. Because future confirmatory work is still
required, these results can instead be seen as suggestive of a
possibly important association. They can also be used to guide the
design of future prospective research.
Such prospective studies are realistic and they should be done.
Going out is not very commonly measured, but use of the SF-36 is
now well-established in Japan, and it is widely used in contexts
ranging from in-hospital RCTs to community-based observational
studies [14,15]. The many ongoing and planned uses of the SF-36
will result in VT scores being recorded, and plans can be made
prospectively to use those scores as sources of information about
how often people go out. Plans can also be made to include, as an
important part of future studies, measurements of the frequency of
going out. If the results of the present study are confirmed, then
information about connections between VT and gai-shutsu might
expand the possibilities for interpreting the results of a wide range
of clinical interventions and social-welfare programs. Asking about
the frequency of gai-shutsu is of course not the only way to explore
the meaning of VT scores, and we hope that other work will
continue putting clinical measurements into concrete and easily
understood terms.
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Figure 3. Association between changes in VT scores and
changes in the frequency of going out. The independent variable
is the categories of SES (SES of ‘‘,0’’ as the reference standard). This
Figure shows the results from model D2, which included age, sex, and
the presence or absence of diabetic nephropathy as covariates. The
odds ratios are almost exactly the same as those shown in Figure 2,
which indicates that the association of increases in VT scores with going
out more frequently was robust even after likely confounders were
accounted for.
doi:10.1371/journal.pone.0040455.g003
Figure 4. Association between changes in VT scores and
changes in the frequency of going out. The independent variable
is the categories of SES (SES of ‘‘,0’’ as the reference standard). This
Figure shows the results from model E2, which was same as Model D2
except that patients whose values were at the floor at baseline were
excluded. Compared with the results of model E2 (Figure 3), the most
noteworthy difference is that the magnitude of the association was
somewhat attenuated in the highest of the four categories of VT
increase. We interpret this result as indicating that the strong
association between increases in VT scores and increases in the
frequency of going out was not caused by regression to the mean.
doi:10.1371/journal.pone.0040455.g004
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